Pasithea Therapeutics
NASDAQ: KTTAVenice, US · Founded 2020 · Delaware corporation · 2 known investors
Pasithea is a biotechnology company focused on the discovery and development of therapeutics for central nervous system disorders and RASopathies. Its research targets conditions including Neurofibromatosis type 1 (NF1), ALS, multiple sclerosis, and schizophrenia.
Founders & leadership
Pasithea Therapeutics was founded in 2020 by Lawrence Steinman and Tiago Reis Marques.
LS
Lawrence SteinmanCo-founder
TR
Tiago Reis MarquesCo-founder
IM
Israel Maxx AbramowitzNamed on SEC filing
CA
Craig AuringerNamed on SEC filing
Investors · 2
Reported raises · per SEC filings
Form D private placements$31.8M disclosed across 3 rounds · 2020–2021
▶$30.4MraisedDec 2021 · 21 investors · BiotechnologyRule 506(b)
▶$30.4MraisedDec 2021 · 21 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Lawrence SteinmanDirector
- Simon DumesnilDirector
- Stanley M. GlossExecutive Officer
- Emer LeahyDirector
- Tiago Andre Dos Reis MarquesExecutive Officer, Director
- Yassine BendiabdallahExecutive Officer, Director
- Offering amount
- $30.4M
- Amount sold
- $30.4M
- Sales commissions
- $2.7M
- Placement agents
- EF Hutton, division of Benchmark Investments, LLC
- First sale
- Nov 2021
- Incorporated
- Corporation, Delaware, 2020
- Federal exemptions
- 06b
▶$1.2MraisedMar 2021 · 30 investors · Other Health CareRule 506(b)
▶$1.2MraisedMar 2021 · 30 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- Lawrence SteinmanDirector
- Tiago Reis MarquesDirector
- Israel Maxx AbramowitzExecutive Officer, Director
- Craig AuringerExecutive Officer, Director
- Offering amount
- $5M
- Amount sold
- $1.2M
- First sale
- Jan 2021
- Incorporated
- Corporation, Delaware, 2020
- Federal exemptions
- 06b
▶$250KraisedJan 2021 · 1 investors · Other Health CareRule 506(b)
▶$250KraisedJan 2021 · 1 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- Lawrence SteinmanDirector
- Tiago Reis MarquesDirector
- Israel Maxx AbramowitzExecutive Officer, Director
- Craig AuringerExecutive Officer, Director
- Offering amount
- $1M
- Amount sold
- $250K
- First sale
- Nov 2020
- Incorporated
- Corporation, Delaware, 2020
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 4
by search overlap
TradingView17 shared keywordsTradingView is a charting platform and social network used by over 100 million traders and investors worldwide to analyze and trade across global financial markets. The platform provides tools for technical analysis, market data, and community collaboration for retail and institutional traders.
Robinhood15 shared keywordsRobinhood is a financial trading platform that enables users to manage portfolios across stocks, ETFs, cryptocurrencies, options, futures, and prediction markets. The platform serves retail investors with low barriers to entry, offering portfolio management services and market insights.
Public14 shared keywordsPublic is a trading platform that allows users to buy and sell cryptocurrencies including Bitcoin, Ethereum, and memecoins through accounts managed by Zero Hash LLC, a New York State-licensed virtual currency business.
Seeking Alpha13 shared keywordsSeeking Alpha is a financial research platform offering stock analysis, market news, investment ideas, and quantitative ratings across asset classes, drawing on a large community of contributing analysts. It serves individual and professional investors seeking research and data-driven insight on stocks and markets.
Companies competing with Pasithea Therapeutics for the same Google search keywords, organic and paid, via search-intersection analysis.
In the news
Frequently asked questions
- What does Pasithea Therapeutics do?
- Pasithea is a biotechnology company focused on the discovery and development of therapeutics for central nervous system disorders and RASopathies. Its research targets conditions including Neurofibromatosis type 1 (NF1), ALS, multiple sclerosis, and schizophrenia.
- Who founded Pasithea Therapeutics?
- Pasithea Therapeutics was founded by Lawrence Steinman, Tiago Reis Marques in 2020.
- Who are Pasithea Therapeutics's investors?
- Pasithea Therapeutics's investors include Vivo Capital, Janus Henderson Investors.
- How much funding has Pasithea Therapeutics raised?
- Pasithea Therapeutics has disclosed $31.8M raised across 3 rounds.
- Where is Pasithea Therapeutics headquartered?
- Pasithea Therapeutics is headquartered in Venice, US.